Gene therapy product shows early promise in sickle cell disease – Healio
|
Gene therapy product shows early promise in sickle cell disease
Healio A 13-year-old boy with sickle cell disease showed no signs of the disease and resumed normal activities 15 months after an infusion of LentiGlobin BB305, according to a study conducted in France and published in The New England Journal of Medicine. |
